{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:46:44Z","timestamp":1783334804544,"version":"3.54.6"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shanghai Scientific and Technological Committee","award":["21Y11908900"],"award-info":[{"award-number":["21Y11908900"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170198"],"award-info":[{"award-number":["82170198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870164"],"award-info":[{"award-number":["81870164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100245"],"award-info":[{"award-number":["82100245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Serum B-cell maturation antigen (sBCMA) levels can serve as a sensitive biomarker in multiple myeloma (MM). In the research setting, sBCMA levels can be accurately detected by enzyme-linked immunosorbent assay (ELISA), but the approach has not been approved for clinical use. Here, we used a novel chemiluminescence method to assess sBCMA levels in 759 serum samples from 17 healthy donors and 443 patients with plasma cell (PC) diseases including AL amyloidosis, POEMS syndrome, and MM. Serum BCMA levels were elevated 16.1-fold in patients with newly diagnosed MM compared to healthy donors and rare PC diseases patients. Specifically, the sBCMA levels in patients with progressive disease were 64.6-fold higher than those who showed partial response or above to treatment. The sBCMA level also correlated negatively with the response depth of MM patients. In newly diagnosed and relapsed MM patients, survival was significantly longer among those subjects whose sBCMA levels are below the median levels compared with those above the median value. We optimized the accuracy of the survival prediction further by integrating sBCMA level into the Second Revised International Staging System (R2-ISS). Our findings provide evidence that the novel chemiluminescence method is sensitive and practical for measuring sBCMA levels in clinical samples and confirm that sBCMA might serve as an independent prognostic biomarker for MM.<\/jats:p>","DOI":"10.1093\/cei\/uxae043","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:35:18Z","timestamp":1715700918000},"page":"221-232","source":"Crossref","is-referenced-by-count":9,"title":["Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma"],"prefix":"10.1093","volume":"217","author":[{"given":"Pei","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-0872","authenticated-orcid":false,"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , Guangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Qiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center , Guangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-4007","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2024080909370788500_CIT0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"2024080909370788500_CIT0002","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"2024080909370788500_CIT0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"2024080909370788500_CIT0004","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"2024080909370788500_CIT0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"2024080909370788500_CIT0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"2024080909370788500_CIT0007","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024080909370788500_CIT0008","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"2024080909370788500_CIT0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12288-018-1029-7","article-title":"Prognostic significance of serum BAFF, APRIL, TACI and BCMA levels in chronic lymphocytic leukemia","volume":"35","author":"Berke Mentese","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2024080909370788500_CIT0010","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/neuonc\/nox097","article-title":"Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma","volume":"19","author":"Thaler","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024080909370788500_CIT0011","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"key":"2024080909370788500_CIT0012","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2024080909370788500_CIT0013","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2024080909370788500_CIT0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2024080909370788500_CIT0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"key":"2024080909370788500_CIT0016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024080909370788500_CIT0017","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjh.16752","article-title":"Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment","volume":"192","author":"Jew","year":"2021","journal-title":"Br J Haematol"},{"key":"2024080909370788500_CIT0018","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1039\/D0CS00348D","article-title":"Chemiluminescence for bioimaging and therapeutics: recent advances and challenges","volume":"49","author":"Yang","year":"2020","journal-title":"Chem Soc Rev"},{"key":"2024080909370788500_CIT0019","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024080909370788500_CIT0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.coi.2021.06.015","article-title":"Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma","volume":"71","author":"Meinl","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2024080909370788500_CIT0021","doi-asserted-by":"crossref","first-page":"1611171","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"2024080909370788500_CIT0022","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.2147\/OTT.S122241","article-title":"Non-secretory multiple myeloma: from biology to clinical management","volume":"9","author":"Dupuis","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2024080909370788500_CIT0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41375-022-01777-w","article-title":"Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma","volume":"37","author":"Liu","year":"2023","journal-title":"Leukemia"},{"key":"2024080909370788500_CIT0024","first-page":"103378","article-title":"Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy","volume":"71","author":"Shen","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"2024080909370788500_CIT0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/hon.2961","article-title":"Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone","volume":"40","author":"Bujarski","year":"2022","journal-title":"Hematol Oncol"},{"key":"2024080909370788500_CIT0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","article-title":"The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker","volume":"18","author":"Sanchez","year":"2018","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae043\/58364911\/uxae043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/3\/221\/58780810\/uxae043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/3\/221\/58780810\/uxae043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:01:14Z","timestamp":1723226474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/217\/3\/221\/7671509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae043","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,14]]}}}